鉴定携带迈克尔接受器核弹头的受约束型模拟剂作为抗类体剂
Santo Previti1, Elsa Calcaterra1, Carla Di Chio1
1Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres 31, 98166, Messina, Italy.
European journal of medicinal chemistry
|February 19, 2025
概括
研究人员开发了针对罗德赛因的新型皮相仿药物,用于治疗松症. 尽管罗德赛因的亲和力降低了,但这些化合物显示出有前途的抗类体活性和低细胞毒性,这表明药物开发的潜力.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 结构-活性关系 (SAR) 研究对于开发有效的抗类体剂至关重要.
- 罗德赛因是治疗松病的关键标.
研究的目的:
- 开发具有抗松体活性的新型罗德赛因向皮模仿药物.
- 为了研究添加1,2,3,4-四化素-3-碳酸 (Tic) 部分对化合物的疗效和安全的影响.
主要方法:
- 合成含有Tic部分的二模化合物 (SPR65-SPR80).
- 化合物对罗德赛因的 afinity 的评价.
- 使用基于细胞的测定 (EC50) 评估抗松体活性.
- 细胞毒性的评估 (CC50).
主要成果:
- 与含有Tic的基因化合物相比,与含有Phenylalanine (Phe) 的基因化合物相比,含有Tic的化合物显示出较低的罗德赛因亲和力.
- 有前途的EC50值 (0.421.35μM) 在基于细胞的抗类体检测中被观察到.
- 高CC50值 (>100μM) 表示细胞毒性较低.
结论:
- 在类迈克尔受体中加入Tic产生了显著的抗类体效应.
- 虫部分可能会改善药物动力学特性或吸引额外的原生动物点,以补偿减少的罗德赛因亲和力.
- 这些发现为未来的SAR研究提供了宝贵的见解,用于抗类药物开发.
更多相关视频
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.0K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
4.9K
相关概念视频
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
